Zobrazeno 1 - 8
of 8
pro vyhledávání: '"John, Ohd"'
Autor:
Bart J Biemond, Anil Tombak, Yurdanur Kilinc, Murtadha Al-Khabori, Miguel Abboud, Mohammed Nafea, Adlette Inati, Yasser Wali, Jens Kristensen, Jan Kowalski, Ellen Donnelly, John Ohd, Erfan Nur, Anita W. Rijneveld, Alibülent Antmen, Marvin Reid, Gabriel Ukala, Lisa Kirven-Dawes, Curis Yeates, Hugh Wong, Abdulrahman Al Sultan
Publikováno v:
Lancet. Haematology, 8(5), e334-e343. Lancet Publishing Group
Summary Background There are no approved treatments for vaso-occlusive crises in sickle cell disease. Sevuparin is a novel non-anticoagulant low molecular weight heparinoid, with anti-adhesive properties. In this study, we tested whether sevuparin co
Autor:
Anil Tombak, Murtadha Al-Khabori, Ellen Donnelly, Miguel R. Abboud, Jens Kristensen, Yurdanur Kilinç, Yasser Wali, John Ohd, Adlette Inati, Mohammed Nafea, Bart J. Biemond
Publikováno v:
Blood. 134:614-614
Background and purpose: There are no currently approved treatments for the vaso-occlusive crises (VOC) associated with sickle cell disease (SCD). In addition to causing pain, vaso-occlusion and the resulting hypoxia cause a reduction in overall life
Autor:
John Ohd, Göran Elmberger, Henrik Hellborg, Johanna Smeds, A-L. Borg, Hans Nordgren, Sigrid Klaar, Lambert Skoog, Jenny Bergqvist, Jorma Isola, Judith Bjöhle, Jonas Bergh
Publikováno v:
Annals of Oncology. 18:845-850
Our aim was to use quantitative real-time PCR (Q-PCR) and RNA expression profiles (RNA-EPs) to investigate HER2 status in relation to outcome.Cut-off levels for Q-PCR and RNA-EP were established in relation to immunohistochemistry (IHC) validated by
Autor:
Birgitta Lindh, Jonas Bergh, Hans Nordgren, Elisabet Lidbrink, Lena Malmberg, Carl Blomqvist, John Ohd, Johan Ahlgren, Daniel Bergström, Kenneth Villman
Publikováno v:
European Journal of Cancer. 43:1153-1160
To assess the efficacy and safety of epirubicin, capecitabine and cisplatin (EXC) combination therapy in locally advanced breast cancer (LABC) and investigate the predictive value of selected biomarkers.Newly diagnosed LABC patients received four 3-w
Autor:
Barbro Linderholm, Judith Bjöhle, John Ohd, Jonas Bergh, Hans Nordgren, Jenny Bergqvist, Göran Elmberger, Anna-Lena Borg, Henrik Hellborg, Lambert Skoog
Publikováno v:
European Journal of Cancer. 42:1104-1112
The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor alpha phosphorylated at S118 (ERalphaS118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen the
Autor:
Sigrid Klaar, Lars Larsson, Jenny Andersson, Göran Carlsson, John Ohd, Jonas Bergh, Bengt Gustavsson, Jan Nilsson, Mats Inganäs, Lars Holmberg, C-M. Rudenstam
Publikováno v:
Annals of Oncology. 16:743-748
Background: TP53 has been described as a prognostic factor in many malignancies, including breast cancer. Whether it also might be a predictive factor with reference to chemo- and endocrine therapy is more controversial. Patients and methods: We inve
Autor:
Carlos A, Rubio, Ragnar, Befrits, Johanna, Osterberg, John, Ohd, Marian L, Miller, Stig, Ramel
Publikováno v:
Anticancer research. 30(1)
A case of massive fundic gland polyposis (MFGPsis) in a female patient receiving protracted proton-pump inhibitor (PPI) medication is described. At gross examination the majority of the polyps were overlapping, confluent, some of them having a "cauli
Autor:
Judith Bjöhle, Chin-Yo Lin, Per Hall, Jonas Bergh, Edison T. Liu, Hans Nordgren, Yudi Pawitan, Alexander Ploner, John Ohd, Lambert Skoog, Sara Wedrén, Fei Huang, Peter M. Shaw, Johanna Smeds, Lance D. Miller
Publikováno v:
BMC Medicine, Vol 4, Iss 1, p 16 (2006)
BMC Medicine
BMC Medicine
Background Postmenopausal hormone-replacement therapy (HRT) increases breast-cancer risk. The influence of HRT on the biology of the primary tumor, however, is not well understood. Methods We obtained breast-cancer gene expression profiles using Affy